The AAIC experience is defined by a diverse scientific program that offers more than 600 podium presentations focusing on basic science and pathogenesis, biomarkers, clinical manifestations, drug development, public health, and dementia care, as well as more than 2,900 posters on the latest dementia research.

More information about the AAIC 2024 program is coming soon.

On This Page:

• Plenary Sessions
• Perspectives Sessions
• Featured Research Sessions

2023 Plenary Sessions

Plenary Sessions address the field’s most crucial and compelling topics and are delivered by leaders in the field. The Alzheimer's Association was pleased to welcome distinguished plenary speakers to AAIC 2023:

Tau PET: Towards Implementation in Trials and Clinical Practice
Presented by Rik Ossenkoppele — Netherlands and Sweden

Bassoon Contributes to Tau-seed Propagation and Neurotoxicity
Presented by Cristian Lasagna-Reeves — United States

The Evolving Role of Complement in Alzheimer’s Disease
Presented by Cynthia Lemere — United States

The Aphasic Dementia of Alzheimer’s Disease
Presented by Marsel Mesulam — United States

The Epidemiology of Dementia in Africa
Presented by Adesola Ogunniyi — Nigeria

Amyloid Reduction and Evidence of Downstream Biomarker Modification
Chairs:

• Catherine J Mummery — United Kingdom
• Jeffrey L. Cummings — United States

Panelists:

• John R. Sims — United States
• Rachelle S. Doody — United States and Switzerland
• Michael C. Irizarry — United States
• Katherine Dawson — United States

An Agenda for Addressing Multimorbidity and Racial and Ethnic Disparities
Presented by Ana Quiñones — United States

Inclusion in Research and Clinical Trials
Presented by Goldie Byrd — United States

2023 Perspectives Sessions

Perspectives Sessions provide expert reviews of recent advances and propose a road map for the future, incorporating multiple viewpoints to stimulate original discussion and debate. Perspectives Sessions at AAIC 2023 included:

• New horizons on human postmortem neuropathology: Driving biomarker and drug development in neurodegenerative diseases.
• Neurodegeneration and inflammation.
• Advances in plasma Alzheimer's disease biomarkers.
• Emerging biomarkers for common co-pathologies.
• The interface of cognition and behavior for dementia risk.
• Dementia care in low- and middle-income countries.
• Novel approaches to address caregiver burden and stress.

Featured Research Sessions

Featured Research Sessions (FRS) debut and discuss innovative and impactful research findings, drawing together multiple studies that share a common focus.